Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
De beurzen gaan herstellen voordat de viruscrisis voorbij is, ook de Amerikaanse futures noteren positief, wat straks tot een positieve opening van Wall Street zou moeten leiden.
Er lijkt een mooi herstel in de maak.Als dit zo blijft tot de slotbel kan dit een bemoedigend teken zijn. succes allen.
Flatlander schreef op 12 maart 2020 16:27 :
www.genomeweb.com/molecular-diagnosti... Ok, today JnJ has announced a CDx agreement with Fisher. Again, like NEO, this is not an exclusive agreement. Someone out there want to opine, why the lab CDx agreements seem to be non exclusive whereas the BCART POC system seems to focus on exclusive agreements. Seems like BCART ought to be receiving a hefty up front premium for going exclusive when they are providing the fastest TAT system on the market. This enables the pharma company to capture more scripts than their competitors. Granted we do not know the terms of the CDx agreements and the milestones. Perhaps it is not an up front payment but rather a CDx approval milestone that is heavily rewarded.
FL
Ok, since no one took the bait to opine, why the lab CDx agreements of our competitors seem to be non-exclusive whereas the BCART POC system seems to focus on exclusive agreements. I'll offer my hypothesis. Part of the value of Idylla is the "ecosystem" that BCART often mentions (but never fully explains what is meant). I think that part of the future intent for the "the ecosystem" is to deliver targeted educational materials and ads that are sponsored by our partners. This would occur when the equipment has traction in the POC market. So targeted ads (and ad revenue at least in the US) are years away, but it goes a long ways toward explaining why exclusive agreements seem to be the norm for BCART but not necessarily its partners. I think BCART made a decision to license CDx to one drug at a time so as not to have the potential of conflicting information for the same indication. I know this is pretty speculative, but if I'm right there are probably some nice milestone payments in the future! FL
De Amerikaanse futures staan stevig in de plus na de tuimeling van donderdag. De future op de Dow Jones staat 5,3 procent hoger, die op de S&P500 5,1 procent en die op de Nasdaq Composite 5,7 procent.
Laup Don't be deceived by the relief rally. The natural reaction after the type of decline we had yesterday is a strong up day. I don't think the market has found a bottom yet. It will be interesting going forward whether BCART trades below the cash on the balance sheet. FL
The more I look at the JnJ and AZN -EGFR CDx issue, the more I believe it could explain a lot. For instance, I can easily see a scenario where the CFO and the CEO might differ on the issue. The CEO should be influenced by the decision most likely to be in the best long term interest of the company. The CFO might well place an emphasis on appeasing one of the company's largest shareholders so as not to cause capital flight. Not to mention, BCART shares space with JnJ in New Jersey and has numerous JnJ employees now working for BCART in the U.S. The CFO might well view the AZN CDx as a unnecessary complication . From the CEO standpoint, it would be foolish to sign a CDx with a JnJ drug that shows promise after Phase I testing vs. a AZN drug already on the market. There simply is too much risk in an early stage drug (no matter how bright the prospects) for any other action to have been taken. I doubt that Renate or BCART would offer comment on this issue since it is likely a sore spot with differing opinions. It would also highlight a division with a major shareholder. From my standpoint, prioritizing solid long term decisions over short term ones that reduce friction is what I want the CEO to do. Unfortunately, it may well be adding to the rough patch that the share price is currently going through. I know this is a lot of conjecture developed around a couple circumstantial facts. FL
Flatlander schreef op 13 maart 2020 14:42 :
The more I look at the JnJ and AZN -EGFR CDx issue, the more I believe it could explain a lot. For instance, I can easily see a scenario where the CFO and the CEO might differ on the issue. The CEO should be influenced by the decision most likely to be in the best long term interest of the company. The CFO might well place an emphasis on appeasing one of the company's largest shareholders so as not to cause capital flight. Not to mention, BCART shares space with JnJ in New Jersey and has numerous JnJ employees now working for BCART in the U.S. The CFO might well view the AZN CDx as a unnecessary complication . From the CEO standpoint, it would be foolish to sign a CDx with a JnJ drug that shows promise after Phase I testing vs. a AZN drug already on the market. There simply is too much risk in an early stage drug (no matter how bright the prospects) for any other action to have been taken.
I doubt that Renate or BCART would offer comment on this issue since it is likely a sore spot with differing opinions. It would also highlight a division with a major shareholder. From my standpoint, prioritizing solid long term decisions over short term ones that reduce friction is what I want the CEO to do. Unfortunately, it may well be adding to the rough patch that the share price is currently going through.
I know this is a lot of conjecture developed around a couple circumstantial facts.
FL
FL, it's a long time before there is a new chief financial officer. Ewoud Welten stays only until the end of March. Don't you think so?
If my explanation is correct, this may have come on in mid January. 60 days would not be unusual to get a new CFO. I think we are close to an announcement. The question is whether it delays the Annual Report. Sufficient time needs to be left for the auditors to certify. I don't think this is a big issue since BCARTs finances seem pretty straight forward. FL
Dank u FL,binnenkort melding JnJ onder de 5% en dat er een nieuwe CFO is.
Iemand een idee wat de beurs gaat doen de volgende dagen?
Ik denk dat het nog een aantal weken zal duren voor we de bodem van deze crisis bereikt hebben, nu veel landen elk op hun beurt beschermende maatregelen treffen.
Historische dalingen zorgen ook voor historische koopkansen.
Een glazen bol zou handig zijn.
Curetis heeft een detectiekit voor coronavirus weet iemand of biocartis daar ook mee bezig is?of is dat een heel ander terrein?
Biocartis had al aangegeven dat ze zich daar niet op zullen toeleggen. Dat lijkt mij overigens een zeer goede keuze. Laat hen maar de focus behouden op de core business, zijnde oncologie. Als ze nu extra cash gaan verbranden om uit te wijken naar Corona testen zal dat op de lange termijn wellicht voor meer problemen dan winst zorgen.
Dank je,duidelijke uitleg daar zit wat in
Voleon Capital heeft zijn shortpositie volledig afgebouwd en ook Highbridge Capital is aan't afbouwen.
Hedge funds rolling up the shorts as BCART trades below cash. Doing anything else would be piggish behavior. As I said a couple of weeks ago, I'm certain we will go into a worldwide recession. Looking out into the 4th quarter, I think there will be a strong rebound. The good news from BCART's perspective is that they have the cash to weather thru this period. They need to focus on the parts of the business that are still achievable while practicing social distancing. Hiring of new sales staff will be delayed. This is an unprecedented event for this generation. We have not seen something like this during the past 100 years. Hopefully it brings out the better side of human nature, rather than the worse. One bright side in the U.S. is that there is a wide realization that Trump is detrimental to the country's future. His own Pandemic adviser Dr. Fauci contradicts him on a daily basis. This is a good thing because the American people are taking the right actions when they are given the facts, even as the government tries to sugar coat it. Best wishes to all! FL
joe123 schreef op 10 maart 2020 09:09 :
[...]
Rerezot dan heb ik een interessante suggestie voor jou,nl AUMANN AG
,een bedrijf die zelfs met uw professioneel werk te maken heeft.
Aumann AG is een toonaangevende wereldwijde leverancier van innovatieve speciale machines en geautomatiseerde productielijnen met een focus op E-mobiliteit.
Op 24 maart 2017kwamen ze op de beurs met een uitgifteprijs van 42 euro en is genoteerd op de Duitse beurs.Het aandeel heeft ondertussen een brokkenpakoer afgelegd.Hoogtepunt in 2018 met een koers van maar liefst 90 euro.Ondertussen is de koers gezakt vanaag tot een dieptepunt van 9,40 euro
Ik kijk met veel belangstelling uit naar uw mening over dit aandeel.
Alvast bedankt..
Joe, Ik ga deze week beginnen aan de analyse voor Aumann :) Rarezot
Rarezot schreef op 16 maart 2020 15:39 :
[...]
Joe,
Ik ga deze week beginnen aan de analyse voor Aumann :)
Rarezot
Ik kijk er naar uit Rarezot.Koers is ondertussen zoals alle nog lager gezakt. Alvast bedankt !!!
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee